Thrombocytopenia Trajectories as a Dynamic Biomarker of Clinical Severity and Survival in Antiphospholipid Syndrome: A Multicenter Cohort Study
Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
Thrombocytopenia is common in antiphospholipid syndrome (APS) and is now included in the 2023 ACR/EULAR APS criteria as an important non criteria/hematologic feature. Persistent or low-moderate thrombocytopenia independently predicts reduced long-term survival in APS, with hazard ratios for mortality around 2.7-4.4, and is associated with a severe disease phenotype and thrombotic deaths.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Age ≥18 years.
• Definite APS by Sydney criteria (thrombotic and/or obstetric) with persistent aPL positivity.
• ≥3 documented platelet counts over ≥12 months before inclusion (to allow trajectory modeling)
Locations
Other Locations
Egypt
New Valley University
RECRUITING
Al Khārjah
Contact Information
Primary
Asmaa N Hussein, MD
asmaanady_1010@med.nvu.edu.eg
01065161752
Time Frame
Start Date: 2026-07-01
Estimated Completion Date: 2027-12-31
Participants
Target number of participants: 200
Treatments
Experimental: Antiphospholipid syndrome patients
* Definite APS by Sydney criteria (thrombotic and/or obstetric) with persistent aPL positivity.~* ≥3 documented platelet counts over ≥12 months before inclusion (to allow trajectory modeling)
Related Therapeutic Areas
Sponsors
Leads: New Valley University